DEA Edibles Packaging Research and Development 
Project CBD
AUGUST 23, 2023
A recent study in the Journal of Cannabis Research revealed that around 85 percent of intoxicating hemp brands lack substantial age verification at checkout. 24 Over 80 percent did not have child-resistant packaging. This is especially troubling in the edible market, where other non-hemp ingredients are present.
Kind Meds (Cannabis Education Blog)
FEBRUARY 7, 2022
The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse. Flower continues to command the market at 43%, but vapes, edibles, and extracts have also become more popular, at 27%, 11%, and 10%, respectively. each year since 2019.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
SEPTEMBER 23, 2019
Marijuana and Cannabinoids: Health, Research and Regulatory Considerations (Position Paper). Barriers to facilitating both clinical and public health research regarding marijuana is detrimental to treating patients and the health of the public. This process should also ensure appropriate funding allocated for this research.
The Joint Blog
SEPTEMBER 19, 2019
Some operators are cashing in on the CBD craze by substituting cheap and illegal synthetic marijuana for natural CBD in vapes and edibles such as gummy bears, an Associated Press investigation has found. It’s Russian roulette,” said James Neal-Kababick, director of Flora Research Laboratories, which tested the products.
Cannabis Law Report
JULY 12, 2019
By: James Holley, Molecular Biologist, Scientific Officer, Mike Robinson, Co-founder, Research Institute, and Dr. David Ostrow, M.D., Research Director. International Cannabinoid Cancer Research Institute (Draft 5). This report (abstract below) asks if Epidiolex is as efficient a drug as the manufacturer believes it to be.
Cannabis Law Report
AUGUST 16, 2019
Congress : “ Cannabis has gone from the butt of jokes on Capitol Hill to milestone hearings and the introduction of landmark legalization reform packages that offer the potential to pave the way for billions of dollars in new business opportunities nationwide. In early August , J.
Cannabis Law Report
AUGUST 6, 2021
Operating expenses : Total SG&A (“SG&A”) expenses in Q1 2022 declined by 17% versus Q1 2021, driven by year-over-year reductions in General & Administrative (“G&A”) and Research and Development (“R&D”) expenses partially offset by an increase in Sales & Marketing (“S&M”) expenses. Excise taxes.
Expert insights. Personalized for you.
141 
Let's personalize your content